SCHEMBL3597067

SCHEMBL3597067

O=C(Nc1ccccc1)Nc1cccc(Nc2ccc3c(c2)/C(=C/c2ccc[nH]2)C(=O)N3)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 6/20 0.76
FLT4 P35916 6/20 0.76
FLT3 P36888 6/20 0.76
PDGFRB P09619 2/20 0.76
TLK2 Q86UE8 5/20 0.71
JAK3 P52333 1/20 0.71
NTRK1 P04629 3/20 0.70
PDPK1 O15530 2/20 0.69
AKT2 P31751 1/20 0.69
PDK1 Q15118 1/20 0.69
KDR P35968 6/20 0.69
NTRK3 Q16288 2/20 0.68
CDK1 P06493 1/20 0.66
CCNB1 P14635 1/20 0.66
NEK2 P51955 1/20 0.66
HDAC3 O15379 1/20 0.61
FLT1 P17948 1/20 0.61
HDAC4 P56524 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597068 1.00 KIT (0.76) KITFLT4FLT3PDGFRBTLK2
SCHEMBL3590029 0.92 FLT3 (0.90) KITFLT4FLT3PDGFRBNTRK1
SCHEMBL3590032 0.92 FLT3 (0.90) KITFLT4FLT3PDGFRBNTRK1
SCHEMBL398830 0.90 TLK2 (0.89) KITFLT4FLT3PDGFRBTLK2
SCHEMBL398831 0.90 TLK2 (0.89) KITFLT4FLT3PDGFRBTLK2
SCHEMBL3603754 0.85 FLT3 (0.89) KITFLT4FLT3PDGFRBNTRK1
SCHEMBL3603752 0.85 FLT3 (0.89) KITFLT4FLT3PDGFRBNTRK1
SCHEMBL3607934 0.85 NTRK1 (0.79) KITFLT4FLT3PDGFRBNTRK1
SCHEMBL3607932 0.85 NTRK1 (0.79) KITFLT4FLT3PDGFRBNTRK1
SCHEMBL3594887 0.83 NTRK1 (0.79) KITFLT4FLT3PDGFRBNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US claimed
EP-2102190-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-09-23 EP claimed
WO-2008073480-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2008-06-19 WO claimed
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US disclosed
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US disclosed
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NTRK2, PDGFRB, PDGFRA KIT 9/4885FLT4 203/4885FLT3 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.